Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Indwelling vs Intermittent Catheterization Pilot Study (PEE)

28 de abril de 2022 atualizado por: Ottawa Hospital Research Institute

Hip Fracture Patient and the Use of IndwElling vs IntermittEnt Catheterization Pilot Study

The primary aim of the proposed pilot feasibility is to determine whether it is feasible to recruit patients with a hip fracture into a prospective study and randomize them to either indwelling or intermittent catheterization. The study hypothesis is that the investigators would be able to show that this study can be incorporated into clinical practice, with satisfactory rate of patient recruitment and retention. Thus, the investigators would be able to compete this pilot study trial and proceed towards a multi-center trial.

Visão geral do estudo

Descrição detalhada

The primary aim of the proposed pilot feasibility is to determine whether it is feasible to recruit patients with a hip fracture into a prospective study and randomize them to either indwelling or intermittent catheterization.

The study hypothesis is that the investigators would be able to show that this study can be incorporated into clinical practice, with satisfactory rate of patient recruitment and retention. Thus, the investigators would be able to compete this vanguard trial and proceed towards a multi-center trial.

Secondary objectives would be related to safety and patient activity that would be important endpoints for the definitive, large scale trial. These would include the following:

  1. Is short term indwelling catheter use associated with reduced incidence of UTI compared to clean intermittent catheterization in patients with hip fracture.
  2. How does patient experience compare between these two forms of treatment?

Eligible patients will be approached for consent at admission and, if willing to participate, will be randomized into Group A or Group B using a web-based, computer-generated randomization with permuted blocks of varying sizes.

Data Collection will include:

  • Urinary symptoms at admission, pre-fracture
  • Date and time of catheter insertion (indwelling or not)
  • Date and time of surgery
  • Type of anesthesia used
  • Date and time of catheter removal
  • Number of catheterizations performed during hospital stay
  • Type of Antibiotic cover during per-operative period (typically 3 doses provided perioperatively)

A clinical research coordinator (CRC) will oversee study recruitment and assess number of study participants to the total number of patients admitted with a hip fracture which will allow for documentation of ability to recruit into the study. Furthermore, the CRC will prospectively record each patent's journey to assess whether enrolled patients are receiving the treatment they are randomized to. All enrolled patients will be asked to fill in a patient satisfaction score that has been in use already at our institution.

A CRC, blinded to the arm patients were randomized to, will be responsible for recording all outcome measures of interest prospectively in the study's database from the participant's electronic medical records. Validity of data extraction will be tested for a randomly selected 10% of the cohort by a second evaluator (CRC not previously involved in the study).

Data analyses will include:

Descriptive Statistics: Given the feasibility purpose of the vanguard trial, descriptive statistics will be used to summarize demographics and baseline prognostic factors of participants allocated to the two trial arms.

Analysis of Primary Outcome: Our primary endpoint is the rate of enrolment to ensure the ability to undertake a larger multi-centered trial. An average rate of 10 patients/month or greater will be considered as ideal for establishing feasibility. An enrollment of less than 5 patients/month will likely jeopardize the ability to feasibly recruit for the larger trial. Whereas, average monthly enrolment of 5 to 10 patients will require a re-evaluation of our recruitment strategy, intervention specifications, and/or eligibility criteria to improve enrolment.

Analysis of Secondary Outcomes: Given the vanguard nature of this trial, the investigators will not undertake inferential analyses of our secondary outcomes but rather these patients will be carried forward into the larger trial.

Tipo de estudo

Intervencional

Inscrição (Antecipado)

120

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Isabel Horton
  • Número de telefone: 73032 613-737-8899
  • E-mail: ihorton@ohri.ca

Estude backup de contato

Locais de estudo

    • Ontario
      • Ottawa, Ontario, Canadá, K1H 8L6
        • The Ottawa Hospital
        • Contato:
          • Isabel S Horton
          • Número de telefone: 73032 6137378899
          • E-mail: ihorton@ohri.ca

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

50 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Hip fracture (intertrochanteric, femoral neck, femoral head, sub-trochanteric) confirmed by imaging
  • Age ≥50 years
  • Operative treatment planned
  • Admitted under Orthopaedic Surgery
  • Willing and able to sign consent (substitute decision maker)

Exclusion Criteria:

  • Periprosthetic hip fracture
  • Polytrauma
  • Multiple fractures of the lower limbs
  • Previous lower urinary tract surgery
  • Known (past or current) urogenital cancer (prostate, bladder)
  • Urinary tract infection prior to randomization
  • Indwelling catheter present on admission (chronic or placed at previous acute setting)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Outro
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Indwelling
Foley catheterization upon admission and removed the morning following surgery.
Patients in the experimental group will receive foley catheter upon admission, aseptically. The catheter will be discontinued on the morning following surgery. At TOH most (>75%) hip fractures are treated within 48 hours of admission and 95% within 72 hours and hence the indwelling catheter is likely to stay in place for 3-4 days.
Experimental: Intermittent
Intermittent catheterization when post-void residual volume is greater than 400 mL.

Patients randomized to the intermittent catheterization group will have their PVR monitored every 8 hours pre-operatively. If PVR>400 mL, an intermittent catheter will be used. If PVR> 400 mL greater than 3 times pre-operatively, an indwelling catheter will be placed the fourth time. The indwelling catheter will be removed the morning of post-op day 1.

It is expected that a small percentage of patients in either group will not have a PVR>400 mL preoperatively.

These patients will not be catheterized but will remain in the study. Post-operatively, both treatment groups will have their PVR monitored for 24 hours, or until PVR is less than 200 mL. If PVR>400 mL and the patient is not able to void further, intermittent catheterization will be done every six hours as needed. If post-operative PVR>400 mL greater than 3 times post-operatively, an indwelling catheter will be placed the fourth time.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Study Feasibility - Enrollment
Prazo: One year

Number of participants enrolled and willingness of participants to be randomized Comparing the Number of patients screened compared to the number of patients meeting eligibility criteria.

Tracking crossover between the treatment groups, participant retention, and follow-up rates.

One year
Study Feasibility - Screening
Prazo: One year
Number of patients screened and number meeting eligibility
One year
Study Feasibility - Retention
Prazo: One year
Participant retention rate in study
One year
Study Feasibility - Follow-up
Prazo: One year
Rates of participant follow-up
One year

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Safety-Related Outcomes - Rates of UTI
Prazo: 30 days
Number of patients who present with a post-operative UTI within 30 days of catheterization
30 days
Safety-Related Outcomes - Rates of POUR
Prazo: 30 days
Number of patients who present with post-operative POUR within 30 days of catheterization
30 days
patient experience questionnaire
Prazo: pre-operatively, and post-operative day six or at discharge
the patient experience questionnaire, created by the principal investigator of the study, will be used to assess patients level of urogenital pain and discomfort and satisfaction with catheterization.
pre-operatively, and post-operative day six or at discharge

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Colaboradores

Investigadores

  • Investigador principal: George Grammatopoulos, MD, The Ottawa Hospital
  • Investigador principal: Steven Papp, MD, The Ottawa Hospital

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Antecipado)

1 de junho de 2022

Conclusão Primária (Antecipado)

1 de maio de 2023

Conclusão do estudo (Antecipado)

1 de julho de 2023

Datas de inscrição no estudo

Enviado pela primeira vez

11 de abril de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

28 de abril de 2022

Primeira postagem (Real)

2 de maio de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

2 de maio de 2022

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de abril de 2022

Última verificação

1 de abril de 2022

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever